ArtiFex Medical GmbH

In cursus massa eget lorem blandit elementum quis luctus libero. Ut venenatis consequat dui, vitae dignissim lacus. In consectetur libero ac aliquet sagittis. Duis facilisis imperdiet lacus at commodo. In vitae ante sem. Maecenas ut elementum ex, non scel

We are conducting ongoing studies to refine the structural properties of bio-engineered cellulose for next-generation graft applications. Preliminary results indicate potential breakthroughs in elasticity and long-term durability. Stay tuned for more insi

Our team is currently exploring new methods to optimize bacterial-cellulose scaffolding for enhanced vascular integration. Early findings suggest promising improvements in mechanical stability and tissue compatibility. Further research updates will be sha

Our new website is coming soon, bringing a clearer look into Artifex's work and vision. Here you'll be able to follow our latest updates, research progress, and developments in bacterial-cellulose vascular grafts. We can't wait to share more as we continu

We use bacterial cellulose, a naturally produced polymer with a nanofibrillar structure that closely mimics soft tissue. Unlike plant-derived cellulose, it contains no lignin or hemicellulose, giving it exceptional purity and biocompatibility. Its three-d

Contributes venture-building experience across R&D, early commercialization and med-tech scale-up, enabling a clear pathway from innovation to a sustainable company.

Leads scientific development with expertise in biomaterials, graft characterization and translational engineering. She ensures the technology meets preclinical, regulatory and manufacturability requirements.

Provides the clinical foundation of the project as a cardiac surgeon and inventor. He guides graft design, surgical usability and clinical validation to ensure strong relevance for CABG and dialysis applications.

Brings extensive med-tech leadership in therapy development, commercialization and organizational execution. He drives strategy, partnerships and the transition from technology to clinical and market adoption. Praesent varius, nisl id maximus gravida, era